Your Messages Inbox
Your Article Summary
See Latest Articles
Abbott announced today that it has entered into an agreement with Pfizer Inc to develop a molecular diagnostic test intended to screen non–small cell lung cancer tumors for the presence of gene rearrangements. Pfizer has developed a novel investigational agent that selectively targets cancer–causing genes implicated in the progress of many cancers. To be eligible to receive Pfizer's oral therapy, a particular genetic translocation known to be found in NSCLC tumors and a wide variety of other cancers, but not in normal cells, must be present.
Today in M&A/Partnerships...keeping you current
Receive free subspecialty "5-minute updates" via email
Bayer CropScience and FuturaGene sign license agreement for drought tolerance technology in cotton
BayNews International, 12/04/09
Sanofi-aventis enters into an Exclusive Global Licensing Agreement with The Rockefeller University
Sanofi-aventis, 12/04/09
Watson Receives FTC Clearance for Arrow Acquisition
Watson Pharmaceuticals, 12/03/09
Article Search
Sponsor